-2%
Teripen is indicated for the treatment of osteoporosis in patients at high risk of fractures. It is used for:
- Postmenopausal women with osteoporosis are at significant fracture risk.
- Men with primary or hypogonadal osteoporosis are at high risk of bone fractures.
- Men and women with osteoporosis resulting from prolonged systemic glucocorticoid therapy where there is increased susceptibility to fractures.
Teriparatide is a synthetic form of the first 34 amino acids of the human parathyroid hormone (PTH), which is the biologically active region. Endogenous PTH plays a crucial role in maintaining calcium and phosphate balance by regulating bone remodeling, renal calcium reabsorption, and intestinal calcium absorption. Teriparatide binds with high affinity to PTH receptors on osteoblasts and renal tubular cells.
Unlike chronic PTH exposure, which may lead to bone resorption (as seen in hyperparathyroidism), once-daily subcutaneous administration of Teriparatide promotes new bone formation by preferentially activating osteoblasts over osteoclasts. This results in increased bone mass and strength in both cortical and trabecular bone. In clinical and animal studies, Teriparatide enhanced bone microarchitecture and significantly improved skeletal integrity.